Tocqueville Asset Management L.P. grew its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 8.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 252,202 shares of the biopharmaceutical company’s stock after purchasing an additional 19,800 shares during the period. Tocqueville Asset Management L.P. owned about 0.16% of Nektar Therapeutics worth $6,053,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the business. Crossmark Global Holdings Inc. purchased a new stake in Nektar Therapeutics during the third quarter worth about $704,000. Boston Advisors LLC purchased a new stake in Nektar Therapeutics during the third quarter worth about $467,000. Nationwide Fund Advisors increased its stake in Nektar Therapeutics by 67.2% during the third quarter. Nationwide Fund Advisors now owns 179,877 shares of the biopharmaceutical company’s stock worth $4,317,000 after purchasing an additional 72,322 shares during the period. Strs Ohio increased its stake in Nektar Therapeutics by 16.3% during the third quarter. Strs Ohio now owns 16,400 shares of the biopharmaceutical company’s stock worth $393,000 after purchasing an additional 2,300 shares during the period. Finally, Gs Investments Inc. purchased a new stake in Nektar Therapeutics during the second quarter worth about $1,006,000. Institutional investors own 95.13% of the company’s stock.
Nektar Therapeutics (NASDAQ:NKTR) opened at $23.75 on Friday. The company has a current ratio of 3.97, a quick ratio of 3.82 and a debt-to-equity ratio of 72.60.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The company had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. During the same period in the prior year, the firm posted ($0.36) earnings per share. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. analysts predict that Nektar Therapeutics will post -0.95 EPS for the current year.
In related news, CEO Howard W. Robin sold 83,334 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $23.57, for a total value of $1,964,182.38. Following the completion of the transaction, the chief executive officer now directly owns 235,838 shares of the company’s stock, valued at $5,558,701.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Jillian B. Thomsen sold 2,648 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total value of $51,159.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 623,317 shares of company stock valued at $14,352,710. Corporate insiders own 6.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Tocqueville Asset Management L.P. Acquires 19,800 Shares of Nektar Therapeutics (NKTR)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/11/05/tocqueville-asset-management-l-p-acquires-19800-shares-of-nektar-therapeutics-nktr.html.
A number of brokerages have issued reports on NKTR. Jefferies Group LLC reiterated a “buy” rating and set a $23.00 price target on shares of Nektar Therapeutics in a research note on Friday, July 21st. Roth Capital set a $33.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Evercore ISI began coverage on shares of Nektar Therapeutics in a research note on Thursday, August 17th. They set an “in-line” rating and a $20.00 price target on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $26.80.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
What are top analysts saying about Nektar Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nektar Therapeutics and related companies.